These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26882623)

  • 1. Drug Pricing Regulation Pushed From Many Sides.
    Kirkner RM
    Manag Care; 2016 Jan; 25(1):14-5. PubMed ID: 26882623
    [No Abstract]   [Full Text] [Related]  

  • 2. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2014 Dec; ():1-38. PubMed ID: 25771555
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
    [No Abstract]   [Full Text] [Related]  

  • 5. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA chief attacks Canada's drug price controls.
    Webster P
    Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
    [No Abstract]   [Full Text] [Related]  

  • 8. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
    [No Abstract]   [Full Text] [Related]  

  • 10. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 11. Should the patent system for new medicines be abolished?
    DiMasi JA; Grabowski HG
    Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
    [No Abstract]   [Full Text] [Related]  

  • 12. Where does drug importation stand now?
    Guglielmo WJ
    Med Econ; 2005 Mar; 82(6):42, 44, 46. PubMed ID: 15869085
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
    Meron D
    Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
    [No Abstract]   [Full Text] [Related]  

  • 14. Manufacturers urge German government to revise proposals for pricing new drugs.
    Stafford N
    BMJ; 2012 Jun; 344():e4069. PubMed ID: 22695911
    [No Abstract]   [Full Text] [Related]  

  • 15. The ethics and economics of pharmaceutical pricing.
    Parker-Lue S; Santoro M; Koski G
    Annu Rev Pharmacol Toxicol; 2015; 55():191-206. PubMed ID: 25149920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 17. CETA: a win for Canada or European pharma?
    Webster PC
    CMAJ; 2014 Oct; 186(15):E565-6. PubMed ID: 25267767
    [No Abstract]   [Full Text] [Related]  

  • 18. Bringing business risk into sharp focus.
    Gruber B; Walsh E
    Nat Biotechnol; 2012 Jan; 30(1):30-2. PubMed ID: 22231088
    [No Abstract]   [Full Text] [Related]  

  • 19. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It?
    Hyman DA; Silver C
    J Leg Med; 2019; 39(2):137-149. PubMed ID: 31503533
    [No Abstract]   [Full Text] [Related]  

  • 20. Ask your doctor: Justice Holmes and the marketplace of ideas.
    Weissmann G
    FASEB J; 2009 Dec; 23(12):4039-42. PubMed ID: 19948522
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.